SGX rejects Thomson Medical’s application to extend period for public float restoration

The company applied for a further extension on 2 January.

Thomson Medical failed to get approval from the Singapore Exchange to extend the period given to them to restore their public float.

In a bourse filing, the company said it sought another extension from the bourse on 2 January.

The first extension granted by the SGX to Thomson Medical ended on 10 January.

Despite SGX’s rejection of the company’s application, Thomson Medical said trading of its shares on the mainboard will continue.

The company also assured the public that it will continue to explore possible options to restore its public float as soon as possible.

Follow the link s for more news on

SGX

Thomson Medical

Reaching the people who run Asia's businesses is harder than it used to be.

Inboxes are crowded. Attention is short. The executives you most want to reach — the founders, CFOs, and operators who actually move budgets — are the hardest to find through the usual channels. If you're building a company, a category, or a reputation, you already know this.

We've spent twenty years building the room they read. Singapore Business Review is where senior decision makers in Singapore and across Southeast Asia come for business coverage they can't get elsewhere — in print, online, and in person at the summits and roundtables we host across seven markets.

If you have something these readers should know about — a point of view worth publishing, a product worth their attention, an event worth their time — we'd like to hear what you're trying to do.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia